• Twice weekly matrix patches releasing approximately 25, 37.5 (Estradot® only), 50, 75 & 100 microgram/24 hours (Estradot®,Evorel®, Estraderm® MX);
• Weekly matrix patches releasing approximately 25, 50, 75 & 100 microgram/24 hours (Femseven®);
• Once weekly matrix patches releasing approx. 50 & 100 microgram estradiol/24 hours (Progynova TS®)
• Estradiol 0.1% gel (Sandrena®)
• Estradiol 0.06% gel (Oestrogel®) 
  
  • Approved for use in gender dysphoria therapy 
  • Approved for use as hormone replacement therapy
• Estradiol 1.53mg/spray transdermal spray (Lenzetto®)
  
  • Approved as an alternative to patches and gels for patients who have issues with absorption, find patch adhesive irritating or the gel messy

• 1mg and 2mg tablets

• Note: ethinylestradiol 2microgram tablets are unlicensed.

• Pack of 16 x 1mg estradiol tablets + 12 x 1mg estradiol and 1mg norethisterone tablets

• Femoston® 1/10 Tablets:
  • Pack of 14 x 1mg estradiol tablets + 14 tablets containing estradiol 1mg and dydrogesterone 10mg

• Femoston® 2/10 Tablets:
  • Pack of 14 x 2mg estradiol tablets + 14 tablets containing estradiol 2mg and dydrogesterone 10mg

• 10mg vaginal tablet
  
  • Vagifem®
  • Vagirux® (alternative)
  
  
  

• For use on the advice of specialists in the prevention and treatment of osteoporosis where alternative treatments are inappropriate.

• Levonorgestrel 52mg in a T-shaped intra-uterine system. 
• For idiopathic menorrhagia. Especially in women requiring (reversible) contraception. Also used for protection with endometrial hyperplasia during oestrogen replacement therapy. Lasts for up to 5 years - for use in accordance with agreed guidelines.

Approved Medroxyprogesterone formulations include:

• 2.5mg, 5mg, and 10mg tablets (sometimes used as a progestogen component of HRT).
• 100mg & 200mg tablets (for use in malignant disease see section 8.3.2).
• 50mg in ml injection - see sections 7.3.2.2 for use of  medroxyprogesterone acetate injection in contraception.

• 100mg oral capsules 
• Approved for:
  
  • adjunctive use with estrogen in post-menopausal women with an intact uterus, as hormone replacement therapy (HRT)
  • Perimenopause (off-label)
  • Premature ovarian insufficiency (off-label)
  • Adolescents undergoing pubertal induction following chemotherapy (off-label)
  
  
  

• Approved formulations include:
  
  • 200mg & 400mg pessaries (Cyclogest®) 
  • 25mg SC/IM injection (Lubion®) 
    
    • Approved for luteal support in patients who have had a previous failed biochemical pregnancy in a froxen embryo transfer (FET) cycle
• CD&TV  for Luteal Phase support following IVF.
  • Full course to be supplied by hospital
• CD&TV   to support the pregnancies of women who have a history of miscarriage or premature labour as per NICE NG25: Preterm labour and birth.

• 5mg tablets
  
  
  • Approved for the pre-operative treatment of uterine fibroids for one 3 month course, as per its product licence.
  • Approved for the medical treatment of uterine fibroids in women unsuitable for surgery, up to a maximum of four 3 month intermittent courses, as per its product licence and reviewed regularly.
  • Contraindicated in women with underlying liver disorders.  
  • Requirements for liver function monitoring before, during, and after treatment

• 250mg/ml solution for injection ampoules

• Gel pump dispenser 16.2mg/g (60 x 1.25g metered doses)  
  • Approved for hypogonadism on the advice of an endocrinologist 
• 2.5g sachets (40.5mg/2.5g)
  • Approved for hypogonadism on the advice of an endocrinologist  
  • Management of low libido in menopausal (both natural and surgical) and post-menopausal women (unlicensed indication) in accordance with attached guidance 

     

• 10mg in 0.5ml (2%)/metered dose
  • Approved for hypogonadism on the advice of an endocrinologist  
  • Management of low libido in menopausal (both natural and surgical) and post-menopausal women (unlicensed indication) in accordance with attached guidance 

• 20mg/g transdermal gel
  • Approved for hypogonadism on the advice of an endocrinologist 

• Sustanon® 250 1ml injection contains testosterone propionate 30mg, testosterone phenylpropionate 60mg, testosterone isocaproate 60mg and testosterone decanoate 100mg.

• 500mcg capsules

• Approved for use on the advice of a urologist.

• 150 micrograms per spray; 268 dose spray

• Tablets: 50mg & 100mg

• Tablets: 25 mg & 100 mg

• Sustanon® 250 1ml injection contains testosterone propionate 30mg, testosterone phenylpropionate 60mg, testosterone isocaproate 60mg and testosterone decanoate 100mg.

• 23 mg/1.15 g (23 mg per actuation); 85.5 g (Testavan^®)
• 50 mg/5 g (50 mg per tube); 30 tubes (Testim^®)
• 16.2 mg/g (20.25 mg per actuation); 88 g (Testogel^®)
• 50 mg/5 g sachet; 30 sachets (Testogel^®)
• 20 mg/g (10 mg per actuation); 60 g (Tostran^®)

1g in 4 mL (250 mg/ml oily injection)

3 mg, 3.75 mg, 11.25 mg and 22.5 mg